Uncategorized
Phage Chemical “Crosstalk” Can Backfire, Steering Responders Into Lysogeny
Phages have been known to trade chemical messages to guide their life‑cycle decisions, but new research shows that some of those messages function more like Trojan horses than helpful signals. By releasing peptides (arbitrium) cues, one phage can mislead another into choosing dormancy at a moment when lysis would normally be favored—a strategic manipulation that shifts the competitive balance between viruses sharing the same bacterial host.
Bacteriophages rely on a simple but consequential choice each time they enter a host cell: burst the cell open to release new viral particles (lysis) or integrate into the genome and lie low (lysogeny). In recent years, researchers have uncovered that some phages don’t make this decision alone. Instead, they use short peptides—part of a communication system known as arbitrium—to optimize their lysis/lysogeny switch. High peptide levels signal that hosts are running out, nudging the phage toward dormancy; low levels encourage lytic growth.
A new study from the University of Exeter titled “Arbitrium phages can manipulate each other’s lysis/lysogeny decisions,” and published in Cell, shows that this viral messaging system isn’t as private as once thought. The team found that arbitrium signals can cross species boundaries, allowing one phage to influence the developmental decisions of another. And in some cases, that influence amounts to a molecular trick: a signal that pushes the receiving phage toward lysogeny even when conditions would normally favor lysis.
The researchers describe this as a form of phage crosstalk—and in certain contexts, a manipulative one. By secreting peptides that resemble the arbitrium signals of other phages, a virus can effectively convince its competitor to stand down. The responding phage enters lysogeny prematurely, sparing the bacterial host and reducing competition for the signaling phage’s own progeny.
“The decision to kill or lie dormant depends on the specific situation,” said Rebecca Woodhams, a PhD student at Exeter’s Centre for Ecology and Conservation. “When many bacteria are available, a phage should choose lysis and look to infect these potential hosts. When many hosts have already been killed, and few remain, lying low and waiting for better times is safer.”
The team demonstrated that non‑cognate peptides—signals produced by unrelated phages—can shift the lysis‑lysogeny balance toward early dormancy. This benefits the phage emitting the signal, which avoids competition, but imposes a fitness cost on the responder, which forgoes opportunities for replication.
Robyn Manley, PhD, a co-author on the study, noted that this dynamic complicates the idea of viral communication as cooperative: “Viral communication is not just cooperation. Sometimes, it is manipulation.”
“Antagonistic co-evolution between signal-emitting and signal-receiving phages to manipulate each other’s infection behaviors may explain the rapid diversification of arbitrium systems and their frequent horizontal exchange to escape the noise of crosstalk,” wrote the authors.
The work was carried out using soil‑associated phages and bacteria, but the implications extend far beyond a single ecological niche. Phage–phage interference like this could ripple through microbial communities, reshaping which bacteria survive and how viral populations compete in shared environments. Understanding how viruses interpret—and misinterpret—chemical cues could help researchers better predict infection outcomes or design phages that resist unwanted crosstalk.
The post Phage Chemical “Crosstalk” Can Backfire, Steering Responders Into Lysogeny appeared first on GEN – Genetic Engineering and Biotechnology News.
Uncategorized
Gilead Swallows Another Partner, Paying up to $5B for ADC Specialist Tubulis
The acquisition of Tubulis GmbH—Gilead Sciences’ latest of the year after buying Arcells and Ouro Medicines—brings into the fold a novel ovarian cancer candidate that has demonstrated promising mid-stage data.
Uncategorized
STAT+: Pharmalittle: We’re reading about FDA backing domestic production, another Gilead deal, and more
Rise and shine, everyone, another busy day is on the way. And it is getting off to a good start here on the Pharmalot campus, where clear blue skies and comfortable breezes are greeting us. Who could ask for anything more? Actually, we could — it is time to reheat the kettle for another cuppa stimulation. Our choice today is ginger peach. And here is a helpful tip — a teaspoon of honey enhances the flavors splendidly. Of course, you are invited to join us. For the full experience, we are now hawking replicas — take a look. Meanwhile, here are a few tidbits to help you along. As always, do keep in touch. We appreciate feedback, criticism, and tips. …
The U.S. Food and Drug Administration used the president’s budget to propose policies aimed at encouraging domestic development and manufacturing of drugs, STAT notes. FDA Commissioner Marty Makary has said the agency needs “giant, big ideas” to counter China’s dominance in early-stage clinical development of drugs. Among the FDA’s ideas are proposals to make it easier to run early-stage trials in the U.S. and to hand an advantage to U.S.-based generics manufacturers. The Trump administration has been using a variety of policy levers to try and bring drug manufacturing to the U.S. One of the legislative proposals in the FDA’s budget justification would let domestic manufacturers of generic drugs challenge brand drug patents a month before foreign companies, a major advantage in an intensely competitive process.
Two more drugmakers, AbbVie and Genentech, will officially start selling their medicines on the TrumpRx website, CBS News tells us. Abbvie, which struck a deal with the Trump administration in January to cut the cost of certain medicines, will sell Humira, a popular medication used to treat rheumatoid arthritis, Crohn’s disease, and ulcerative colitis, on the site at an 86% discount. The prescription prices on the site, however, are only available to patients who are uninsured, or whose insurance does not cover it, and who must pay the full list price out of pocket. Those with insurance coverage generally pay lower prices already. TrumpRx now sells over 61 drugs at a lower price, up from about 40 when the website went live in February.
Rise and shine, everyone, another busy day is on the way. And it is getting off to a good start here on the Pharmalot campus, where clear blue skies and comfortable breezes are greeting us. Who could ask for anything more? Actually, we could — it is time to reheat the kettle for another cuppa stimulation. Our choice today is ginger peach. And here is a helpful tip — a teaspoon of honey enhances the flavors splendidly. Of course, you are invited to join us. For the full experience, we are now hawking replicas — take a look. Meanwhile, here are a few tidbits to help you along. As always, do keep in touch. We appreciate feedback, criticism, and tips. …
The U.S. Food and Drug Administration used the president’s budget to propose policies aimed at encouraging domestic development and manufacturing of drugs, STAT notes. FDA Commissioner Marty Makary has said the agency needs “giant, big ideas” to counter China’s dominance in early-stage clinical development of drugs. Among the FDA’s ideas are proposals to make it easier to run early-stage trials in the U.S. and to hand an advantage to U.S.-based generics manufacturers. The Trump administration has been using a variety of policy levers to try and bring drug manufacturing to the U.S. One of the legislative proposals in the FDA’s budget justification would let domestic manufacturers of generic drugs challenge brand drug patents a month before foreign companies, a major advantage in an intensely competitive process.
Two more drugmakers, AbbVie and Genentech, will officially start selling their medicines on the TrumpRx website, CBS News tells us. Abbvie, which struck a deal with the Trump administration in January to cut the cost of certain medicines, will sell Humira, a popular medication used to treat rheumatoid arthritis, Crohn’s disease, and ulcerative colitis, on the site at an 86% discount. The prescription prices on the site, however, are only available to patients who are uninsured, or whose insurance does not cover it, and who must pay the full list price out of pocket. Those with insurance coverage generally pay lower prices already. TrumpRx now sells over 61 drugs at a lower price, up from about 40 when the website went live in February.
Uncategorized
FDA Seeks Expanded Authority To Regulate Postapproval Manufacturing Changes
FDA Seeks Expanded Authority To Regulate Postapproval Manufacturing Changes
Aiming to protect patients, the FDA sent lawmakers a wish list of legislative proposals intended to clarify and expand its oversight of updates to approved drug production processes. Read More
-
Uncategorized9 years agoThese ’90s fashion trends are making a comeback in 2017
-
Contributors9 years agoThe final 6 ‘Game of Thrones’ episodes might feel like a full season
-
Uncategorized9 years agoAccording to Dior Couture, this taboo fashion accessory is back
-
Uncategorized9 years agoThe old and New Edition cast comes together to perform
-
Uncategorized9 years agoPhillies’ Aaron Altherr makes mind-boggling barehanded play
-
Uncategorized9 years agoUber and Lyft are finally available in all of New York State
-
Uncategorized9 years agoDisney’s live-action Aladdin finally finds its stars
-
Uncategorized9 years agoSteph Curry finally got the contract he deserves from the Warriors